" align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Severe hypoglycemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">In Combination with Insulin Glargine ± Metformin</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">      <span class=\\\"Bold\\\">(28 weeks)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=150</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">-</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=150</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hypoglycemia with a glucose level &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">9.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">14.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Severe hypoglycemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Add-on to SGLT2i ± Metformin</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">      <span class=\\\"Bold\\\">(24 weeks)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=140</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=141</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=142</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hypoglycemia with a glucose level &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Severe hypoglycemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0</td></tr></tbody></table><p>Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week adult clinical trial, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to <a href=\\\"#t3\\\">Table 3</a> for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine.</p><p>In the clinical trial with adult patients on TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, as add-on to metformin, incidences of hypoglycemia (glucose level &lt;54 mg/dL) through 36 weeks were 1.1%, 0.3%, and 1.1%, respectively, and incidences of severe hypoglycemia were 0.2%, 0%, and 0.2%, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29\\\"></a><a name=\\\"section-6.1.1.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Cholelithiasis and Cholecystitis</span></p><p>In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years <span class=\\\"Italics\\\">[see Clinical Studies <a href=\\\"#s89\\\">14.5</a>]</span>, cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s30\\\"></a><a name=\\\"section-6.1.1.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Heart Rate Increase and Tachycardia-Related Adverse Reactions</span></p><p>In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).</p><p>Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s31\\\"></a><a name=\\\"section-6.1.1.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Hypersensitivity</span></p><p>Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on TRULICITY in clinical studies.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s32\\\"></a><a name=\\\"section-6.1.1.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Injection-site Reactions</span></p><p>In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s33\\\"></a><a name=\\\"section-6.1.1.3.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">PR Interval Prolongation and Adverse Reactions of First-Degree Atrioventricular (AV) Block</span></p><p>A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s34\\\"></a><a name=\\\"section-6.1.1.3.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Amylase and Lipase Increase</span></p><p>Adult patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s35\\\"></a><a name=\\\"section-6.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus</span></p><p>TRULICITY was administered to 150 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 41.3 weeks [<span class=\\\"Italics\\\">see Clinical Studies (<a href=\\\"#s90\\\">14.6</a>)</span>]. The mean age was 14.5 years and 71% of patients were female. Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m<span class=\\\"Sup\\\">2</span>.</p><p>The safety profile in pediatric patients treated with TRULICITY 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions. In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"90375-7\\\"><a name=\\\"s36\\\"></a><a name=\\\"section-6.2\\\"></a><p></p><h2>6.2 Postmarketing Experience</h2><p class=\\\"First\\\">The following additional adverse reactions have been reported during post-approval use of TRULICITY. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><ul class=\\\"Disc\\\"><li><span class=\\\"Italics\\\">Gastrointestinal:</span> ileus</li><li><span class=\\\"Italics\\\">Hepatobiliary:</span> cholecystitis, cholelithiasis requiring cholecystectomy, cholestasis, elevation of liver enzymes, hepatitis</li><li><span class=\\\"Italics\\\">Hypersensitivity:</span> anaphylactic reactions, angioedema</li><li><span class=\\\"Italics\\\">Nervous System Disorders</span>: dysgeusia</li><li><span class=\\\"Italics\\\">Pulmonary:</span> Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.</li><li><span class=\\\"Italics\\\">Renal:</span> acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis</li></ul></div></section>\",\n            \"drugInteractions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34073-7\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-7\\\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s38\\\"></a><a name=\\\"section-7.1\\\"></a><p></p><h2>7.1 Oral Medications</h2><p class=\\\"First\\\">TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.1</a>)]</span>. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s64\\\">12.3</a>)]</span>. There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg.</p><p>Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s39\\\"></a><a name=\\\"section-7.2\\\"></a><p></p><h2>7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</h2><p class=\\\"First\\\">When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s14\\\">5.3</a>) and Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>)].</span></p></div></section>\",\n            \"clinicalPharmacology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34090-1\\\"><a name=\\\"s56\\\"></a><a name=\\\"section-11\\\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43681-6\\\"><a name=\\\"s58\\\"></a><a name=\\\"section-11.2\\\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\\\"First\\\">TRULICITY lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s59\\\"></a><a name=\\\"section-11.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Fasting and Postprandial Glucose</span></p><p>In a clinical pharmacology study in patients with type 2 diabetes mellitus, treatment with once weekly TRULICITY resulted in a reduction of fasting and 2-hour PPG concentrations, and postprandial serum glucose incremental AUC, when compared to placebo (-25.6 mg/dL, -59.5 mg/dL, and -197 mg*h/dL, respectively); these effects were sustained after 6 weeks of dosing with the 1.5 mg dose.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s60\\\"></a><a name=\\\"section-11.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">First- and Second-Phase Insulin Secretion</span></p><p>Both first- and second-phase insulin secretion were increased in patients with type 2 diabetes treated with TRULICITY compared with placebo.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s61\\\"></a><a name=\\\"section-11.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Insulin and Glucagon Secretion</span></p><p>TRULICITY stimulates glucose-dependent insulin secretion and reduces glucagon secretion. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly increased fasting insulin from baseline at Week 26 by 35.38 and 17.50 pmol/L, respectively, and C-peptide concentration by 0.09 and 0.07 nmol/L, respectively, in a monotherapy trial. In the same trial, fasting glucagon concentration was reduced by 1.71 and 2.05 pmol/L from baseline with TRULICITY 0.75 mg and 1.5 mg, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s62\\\"></a><a name=\\\"section-11.2.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Gastric Motility</span></p><p>Dulaglutide causes a delay of gastric emptying. The delay in gastric emptying is dose-dependent but is attenuated with adequate dose escalation to higher doses of TRULICITY. The delay is largest after the first dose and diminishes with subsequent doses.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63\\\"></a><a name=\\\"section-11.2.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Cardiac Electrophysiology (QTc)</span></p><p>The effect of dulaglutide on cardiac repolarization was tested in a thorough QTc study. Dulaglutide did not produce QTc prolongation at doses of 4 and 7 mg. The maximum recommended dose is 4.5 mg once weekly.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"43682-4\\\"><a name=\\\"s64\\\"></a><a name=\\\"section-11.3\\\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\\\"First\\\">The pharmacokinetics of dulaglutide is similar between healthy subjects and patients with type 2 diabetes mellitus. Following subcutaneous administration, the time to maximum plasma concentration of dulaglutide at steady state ranges from 24 to 72 hours, with a median of 48 hours. After reaching steady state, the accumulation ratio was approximately 1.56. Steady-state plasma dulaglutide concentrations were achieved between 2 and 4 weeks following once weekly administration. Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide.</p><p><span class=\\\"Underline\\\">Absorption</span> – The mean absolute bioavailability of dulaglutide following subcutaneous administration of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively. Absolute subcutaneous bioavailability for 3 mg and 4.5 mg doses were estimated to be similar to 1.5 mg although this has not been specifically studied. Dulaglutide concentrations increased approximately proportional to dose from 0.75 mg to 4.5 mg.</p><p><span class=\\\"Underline\\\">Distribution</span> – Apparent population mean central volume of distribution was 3.09 L and the apparent population mean peripheral volume of distribution was 5.98 L.</p><p><span class=\\\"Underline\\\">Elimination</span></p><p>The apparent population mean clearance of dulaglutide was 0.142 L/h. The elimination half-life of dulaglutide was approximately 5 days.</p><p><span class=\\\"Italics\\\">Metabolism</span> – Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s65\\\"></a><a name=\\\"section-11.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Populations</span></p><p>The intrinsic factors of age (≥ 65 years), sex, race, ethnicity, body weight, or renal or hepatic impairment did not have a clinically relevant effect on the PK of dulaglutide as shown in <a href=\\\"#f01\\\">Figure 1</a>.</p><div class=\\\"Figure\\\"><a name=\\\"f01\\\"></a><img alt=\\\"Figure 1\\n\\\" src=\\\"trulicity-pi-f1-v2.jpg\\\"/></div><p>Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; C<span class=\\\"Sub\\\">max</span> = maximum concentration; ESRD = end-stage renal disease; PK = pharmacokinetics.</p><p>Note: Reference values for weight, age, gender, and race comparisons are 93 kg, 56 years old, male, and white, respectively; reference groups for renal and hepatic impairment data are subjects with normal renal and hepatic function from the respective clinical pharmacology studies. The weight values shown in the plot (70 and 120 kg) are the 10<span class=\\\"Sup\\\">th</span> and 90<span class=\\\"Sup\\\">th</span> percentiles of weight in the PK population.</p><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 1: Impact of intrinsic factors on dulaglutide pharmacokinetics.</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s66\\\"></a><a name=\\\"section-11.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Pediatric Patients</span></p><p>A population pharmacokinetic analysis was conducted for dulaglutide 0.75 mg and 1.5 mg using data from 128 pediatric patients 10 years of age and older with type 2 diabetes mellitus. The AUC in pediatric patients was approximately 37% lower than that in adult patients. However, this difference was not determined to be clinically meaningful.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s67\\\"></a><a name=\\\"section-11.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Renal Impairment</span></p><p>Dulaglutide systemic exposure was increased by 20, 28, 14 and 12% for mild, moderate, severe, and ESRD renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in C<span class=\\\"Sub\\\">max</span> were 13, 23, 20 and 11%, respectively (<a href=\\\"#f01\\\">Figure 1</a>). Additionally, in a 52 week clinical trial in patients with type 2 diabetes mellitus and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies <span class=\\\"Italics\\\">[see Warning and Precautions (<a href=\\\"#s16\\\">5.5</a>), Use in Specific Populations (<a href=\\\"#s51\\\">8.6</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s68\\\"></a><a name=\\\"section-11.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Hepatic Impairment</span></p><p>Dulaglutide systemic exposure decreased by 23, 33 and 21% for mild, moderate and severe hepatic impairment groups, respectively, compared to subjects with normal hepatic function, and C<span class=\\\"Sub\\\">max</span> was decreased by a similar magnitude (<a href=\\\"#f01\\\">Figure 1</a>) <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s52\\\">8.7</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69\\\"></a><a name=\\\"section-11.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Drug Interaction Studies</span></p><p>The potential effect of co-administered medications on the PK of dulaglutide 1.5 mg and vice versa was studied in several single- and multiple-dose studies in healthy subjects, patients with type 2 diabetes mellitus, and patients with hypertension.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70\\\"></a><a name=\\\"section-11.3.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs</span></p><p>Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally co-administered medications. In clinical pharmacology studies, dulaglutide at a dose of 1.5 mg did not affect the absorption of the tested orally administered medications to any clinically relevant degree. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.1</a>), Drug Interactions (<a href=\\\"#s38\\\">7.1</a>)]</span>. The delay is largest after the first dose and diminishes with subsequent doses. PK measures indicating the magnitude of these interactions are presented in <a href=\\\"#f02\\\">Figure 2</a>.</p><div class=\\\"Figure\\\"><a name=\\\"f02\\\"></a><img alt=\\\"Figure 2\\n\\\" src=\\\"trulicity-pi-f2-v2.jpg\\\"/></div><p>Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; C<span class=\\\"Sub\\\">max</span> = maximum concentration; PK = pharmacokinetics.</p><p>Note: Reference group is co-administered medication given alone.</p><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 2: Impact of dulaglutide 1.5 mg on the pharmacokinetics of co-administered medications.</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s71\\\"></a><a name=\\\"section-11.3.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Potential for Co-administered Drugs to Influence the Pharmacokinetics of Dulaglutide</span></p><p>In a clinical pharmacology study, the co-administration of a single dose of 1.5 mg dulaglutide with steady-state dose of 100 mg sitagliptin caused an increase in dulaglutide AUC and C<span class=\\\"Sub\\\">max</span> of approximately 38% and 27%, which is not considered clinically relevant.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"88830-5\\\"><a name=\\\"s72\\\"></a><a name=\\\"section-11.4\\\"></a><p></p><h2>12.6 Immunogenicity</h2><p class=\\\"First\\\">The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.</p><p>In glycemic control trials in adults with type 2 diabetes mellitus (monotherapy and combination therapy) <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s78\\\">14.2</a>, <a href=\\\"#s79\\\">14.3</a>)]</span>, during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA)).  Of the 64 TRULICITY-treated patients that developed ADA, 34 patients (0.9% of the overall population) developed dulaglutide-neutralizing antibodies, and 36 patients (0.9% of the overall population) developed antibodies against native GLP-1. There was no identified clinically significant effect of ADA on pharmacokinetics, pharmacodynamics, safety, or effectiveness of TRULICITY over the 24 to 104 week treatment duration in the trials in adults with type 2 diabetes mellitus.</p><p>During the 26-week controlled period of the glycemic control trial in pediatric patients 10 years of age or older with type 2 diabetes mellitus <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s90\\\">14.6</a>)]</span>, 4/101 (4%) of TRULICITY-treated pediatric patients developed ADA. Of the 4 pediatric patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 3 patients (3% of the overall population) developed antibodies against native GLP-1. During the 52-week postbaseline period of the same trial (through safety follow-up), 6/103 (6%) of TRULICITY-treated patients developed ADA. Of the 6 patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 4 patients (4% of the overall population) developed antibodies against native GLP-1. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of TRULICITY is unknown in pediatric patients.</p></div></section>\",\n            \"clinicalStudies\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34092-7\\\"><a name=\\\"s76\\\"></a><a name=\\\"section-13\\\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s77\\\"></a><a name=\\\"section-13.1\\\"></a><p></p><h2>14.1 Overview of Clinical Trials</h2><p class=\\\"First\\\">TRULICITY has been studied in adults as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin. TRULICITY has also been studied in patients with type 2 diabetes mellitus and moderate to severe renal impairment.</p><p>Dose escalation was performed in one trial in adults with TRULICITY doses up to 4.5 mg added to metformin. All other clinical studies in adults evaluated TRULICITY 0.75 mg and 1.5 mg without dose escalation; patients were initiated and maintained on either 0.75 mg or 1.5 mg for the duration of the trials <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s78\\\">14.2</a>, <a href=\\\"#s79\\\">14.3</a>, <a href=\\\"#s88\\\">14.4</a>)]</span>.</p><p>TRULICITY 0.75 mg and 1.5 mg was studied in pediatric patients 10 years of age and older with type 2 diabetes in combination with or without metformin and/or basal insulin treatment <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s90\\\">14.6</a>)]</span>.</p><p>In patients with type 2 diabetes mellitus, TRULICITY produced reductions from baseline in HbA1c compared to placebo. No overall differences in glycemic effectiveness were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes).</p><p>A cardiovascular outcomes trial was conducted in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors. Patients were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s89\\\">14.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s78\\\"></a><a name=\\\"section-13.2\\\"></a><p></p><h2>14.2 Glycemic Control Monotherapy Trials in Adults with Type 2 Diabetes Mellitus</h2><p class=\\\"First\\\">In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or metformin 1500 to 2000 mg/day following a two-week washout. Seventy-five percent (75%) of the randomized population were treated with one antidiabetic agent at the screening visit. Most patients previously treated with an antidiabetic agent were receiving metformin (~90%) at a median dose of 1000 mg daily and approximately 10% were receiving a sulfonylurea.</p><p>Patients had a mean age of 56 years and a mean duration of type 2 diabetes of 3 years. Forty-four percent were male. The White, Black and Asian race accounted for 74%, 7% and 8% of the population, respectively. Twenty-nine percent of the trial population were from the US.</p><p>Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in reduction in HbA1c from baseline at 26-weeks (<a href=\\\"#t4\\\">Table 4</a>). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and metformin excluded the pre-specified non-inferiority margin of 0.4%.</p><a name=\\\"t4\\\"></a><table width=\\\"100%\\\"><caption><span>Table 4: Results at Week 26 in a Trial of TRULICITY as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"49.538%\\\"/><col align=\\\"left\\\" width=\\\"16.821%\\\"/><col align=\\\"left\\\" width=\\\"16.821%\\\"/><col align=\\\"left\\\" width=\\\"16.821%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 10%, 12% and 14% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and metformin, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean adjusted for baseline value and other stratification factors.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡</span> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 265 individuals in each of the treatment arms.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">26-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Metformin <br/>1500-2000 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">‡</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">270</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">269</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">268</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">7.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">7.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">7.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">161</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">164</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">161</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-26</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-29</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-24</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">91.8</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">92.7</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">92.4</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-2.2</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s79\\\"></a><a name=\\\"section-13.3\\\"></a><p></p><h2>14.3 Glycemic Control Combination Therapy Trials in Adults with Type 2 Diabetes Mellitus</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80\\\"></a><a name=\\\"section-13.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Sitagliptin-Controlled Trial (Add-on to Metformin)</span></p><p>In this placebo-controlled, double-blind trial with primary endpoint at 52 weeks, 972 adult patients were randomized to placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or sitagliptin 100 mg/day (after 26 weeks, patients in the placebo treatment group received blinded sitagliptin 100 mg/day for the remainder of the trial), all as add-on to metformin. Randomization occurred after an 11-week lead-in period to allow for a metformin titration period, followed by a 6-week glycemic stabilization period. Patients had a mean age of 54 years; mean duration of type 2 diabetes of 7 years; 48% were male; race: White, Black and Asian were 53%, 4% and 27%, respectively; and 24% of the trial population were in the US.</p><p>At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. The percentage of patients who achieved HbA1c &lt;7.0% was 22%, 56%, 62% and 39% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. At 26 weeks, there was a mean weight reduction of 1.4 kg, 2.7 kg, 3.0 kg, and 1.4 kg for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. There was a mean reduction of fasting glucose of 9 mg/dL, 35 mg/dL, 41 mg/dL, and 18 mg/dL for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively.</p><p>Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to sitagliptin (at 26 and 52 weeks), all in combination with metformin (<a href=\\\"#t5\\\">Table 5</a> and <a href=\\\"#f03\\\">Figure 3</a>).</p><a name=\\\"t5\\\"></a><table width=\\\"100%\\\"><caption><span>Table 5: Results at Week 52 of TRULICITY Compared to Sitagliptin used as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"42.850%\\\"/><col align=\\\"left\\\" width=\\\"19.325%\\\"/><col align=\\\"left\\\" width=\\\"15.975%\\\"/><col align=\\\"left\\\" width=\\\"21.850%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> All ITT patients randomized after the dose-finding portion of the trial. Last observation carried forward (LOCF) was used to impute missing data. At Week 52 primary efficacy was missing for 15%, 19%, and 20% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡</span> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 276, 277, and 270 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">††</span> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to sitagliptin, assessed only for HbA1c.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">##</span> p&lt;0.001 TRULICITY compared to sitagliptin, assessed only for HbA1c &lt;7.0%.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">52-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY<br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY<br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Sitagliptin<br/>100 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">‡</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">281</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">279</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">273</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.9</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from sitagliptin<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.5 (-0.7, -0.3)<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.7 (-0.9, -0.5)<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">49<span class=\\\"Sup\\\">##</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">59<span class=\\\"Sup\\\">##</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">33</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Fasting Plasma Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">174</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">173</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">171</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-30</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-41</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-14</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from sitagliptin<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-15 (-22, -9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-27 (-33, -20)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">85.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">86.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">85.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-2.7</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-3.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.5</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from sitagliptin<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.2 (-1.8, -0.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.5 (-2.1, -0.9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr></tbody></table><div class=\\\"Figure\\\"><a name=\\\"f03\\\"></a><img alt=\\\"Figure 3\\n\\\" src=\\\"trulicity-pi-f3-v3.jpg\\\"/></div><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"19.805%\\\"/><col align=\\\"left\\\" width=\\\"15.104%\\\"/><col align=\\\"left\\\" width=\\\"31.133%\\\"/><col align=\\\"left\\\" width=\\\"33.958%\\\"/><tfoot><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Mean HbA1c adjusted for baseline HbA1c and country.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of patients with observed data</span></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">Placebo</td><td align=\\\"center\\\" valign=\\\"top\\\">139</td><td align=\\\"center\\\" valign=\\\"top\\\">108</td><td align=\\\"center\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">TRULICITY 0.75 mg</td><td align=\\\"center\\\" valign=\\\"top\\\">281</td><td align=\\\"center\\\" valign=\\\"top\\\">258</td><td align=\\\"center\\\" valign=\\\"top\\\">238</td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">TRULICITY 1.5 mg</td><td align=\\\"center\\\" valign=\\\"top\\\">279</td><td align=\\\"center\\\" valign=\\\"top\\\">249</td><td align=\\\"center\\\" valign=\\\"top\\\">225</td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">Sitagliptin</td><td align=\\\"center\\\" valign=\\\"top\\\">273</td><td align=\\\"center\\\" valign=\\\"top\\\">241</td><td align=\\\"center\\\" valign=\\\"top\\\">219</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 3: Adjusted Mean HbA1c at each Time Point (ITT, MMRM) and at Week 52 (ITT, LOCF) in Adult Patients with Type 2 Diabetes Mellitus</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s81\\\"></a><a name=\\\"section-13.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Dosage Ranging Trial of TRULICITY 1.5, 3 mg, and 4.5 mg (Add-on to Metformin)</span></p><p>In this parallel-arm, double-blind trial with primary endpoint at 36 weeks, a total of 1842 adult patients were randomized 1:1:1 to TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, all as add-on to metformin (NCT03495102).</p><p>Following randomization, all patients received TRULICITY 0.75 mg once weekly. The dose was increased every 4 weeks to the next higher dose until the patients reached their assigned dose (1.5 mg, 3 mg, or 4.5 mg). Patients were to remain on the assigned study dose for the duration of the trial.</p><p>Patients had a mean age of 57.1 years; a mean duration of type 2 diabetes of 7.6 years; 51.2% were male; race: White, Black, and Asian were 85.8%, 4.5%, and 2.4%, respectively; and 27.6% of the trial population was in the US.</p><p>At 36 weeks, treatment with TRULICITY 4.5 mg resulted in a statistically significant reduction in HbA1c and in body weight compared to TRULICITY 1.5 mg (<a href=\\\"#t6\\\">Table 6</a> and <a href=\\\"#f04\\\">Figure 4</a>).</p><a name=\\\"t6\\\"></a><table width=\\\"100%\\\"><caption><span>Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.725%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. At Week 36, primary efficacy was missing for 7%, 7%, and 6% of individuals treated with TRULICITY 1.5 mg, TRULICITY 3 mg, and TRULICITY 4.5 mg, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean adjusted for baseline value and other stratification factors. Missing data were imputed using multiple imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Patients with missing HbA1c data at Week 36 were considered as not achieving HbA1c target.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">^ p=0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">^^ p&lt;0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">36-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>3 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>4.5 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">612</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">616</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">614</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from 1.5 mg<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.1 (-0.2, 0.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.2 (-0.4, -0.1) ^</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">50</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">56</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">62</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">185</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">184</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">183</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-45</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-46</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-51</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from 1.5 mg<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">- 2 (-7, 3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-6 (-11, -2)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">95.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">96.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">95.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-3.0</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-3.8</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-4.6</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from 1.5 mg<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.9 (-1.4, -0.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.6 (-2.2, -1.1) ^^</td></tr></tbody></table><div class=\\\"Figure\\\"><a name=\\\"f04\\\"></a><img alt=\\\"Figure 4\\n\\\" src=\\\"trulicity-pi-f4-v3.jpg\\\"/></div><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"22.200%\\\"/><col align=\\\"left\\\" width=\\\"13.125%\\\"/><col align=\\\"left\\\" width=\\\"30.950%\\\"/><col align=\\\"left\\\" width=\\\"33.725%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of patients with observed data</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">TRULICITY 1.5 mg</td><td align=\\\"left\\\" valign=\\\"top\\\">612</td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\">567</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">TRULICITY    3 mg</td><td align=\\\"left\\\" valign=\\\"top\\\">616</td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\">572</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">TRULICITY 4.5 mg</td><td align=\\\"left\\\" valign=\\\"top\\\">614</td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\">575</td></tr></tbody></table><p>Observed mean HbA1c at scheduled visits and retrieved dropout multiple imputation (MI) based estimate at week 36.</p><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 4: Mean HbA1c at each Time Point (ITT) and at Week 36 (ITT, MI)</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s82\\\"></a><a name=\\\"section-13.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Placebo-Controlled Trial (Add-on to Sulfonylurea)</span></p><p>In this 24-week placebo-controlled, double-blind trial, 299 adult patients were randomized to and received placebo or once weekly TRULICITY 1.5 mg, both as add-on to glimepiride. Patients had a mean age of 58 years; mean duration of type 2 diabetes of 8 years; 44% were male; race: White, Black, and Asian were 83%, 4%, and 2%, respectively; and 24% of the trial population were in the US.</p><p>At 24 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo (<a href=\\\"#t7\\\">Table 7</a>).</p><a name=\\\"t7\\\"></a><table width=\\\"100%\\\"><caption><span>Table 7: Results at Week 24 of TRULICITY Compared to Placebo as Add-On to Glimepiride in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.833%\\\"/><col align=\\\"left\\\" width=\\\"32.533%\\\"/><col align=\\\"left\\\" width=\\\"31.633%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. Data post-onset of rescue therapy are treated as missing. At Week 24 primary efficacy was missing for 10% and 12% of individuals randomized to TRULICITY 1.5 mg and placebo, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to the baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 24 data.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Patients with missing HbA1c data at Week 24 were considered as non-responders.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">††</span> p&lt;0.001 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">24-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TRULICITY<br/>1.5 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">60</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">239</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.4</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.1 (-1.4, -0.7)<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">17</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">50<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">175</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">178</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-28</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-30 (-44, -15)<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">89.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">84.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.5</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.4 (-1.2, 0.5)</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s83\\\"></a><a name=\\\"section-13.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Placebo- and Exenatide-Controlled Trial (Add-on to Metformin and Thiazolidinedione)</span></p><p>In this placebo-controlled trial with primary endpoint at 26 weeks, 976 adult patients were randomized to and received placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or exenatide 10 mcg BID, all as add-on to maximally tolerated doses of metformin (≥1500 mg per day) and pioglitazone (up to 45 mg per day). Exenatide treatment group assignment was open-label while the treatment assignments to placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg were blinded. After 26 weeks, patients in the placebo treatment group were randomized to either TRULICITY 0.75 mg once weekly or TRULICITY 1.5 mg once weekly to maintain blinding. Randomization occurred after a 12-week lead-in period; during the initial 4 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and pioglitazone; this was followed by an 8-week glycemic stabilization period prior to randomization. Patients randomized to exenatide started at a dose of 5 mcg BID for 4 weeks and then were escalated to 10 mcg BID. Patients had a mean age of 56 years; mean duration of type 2 diabetes of 9 years; 58% were male; race: White, Black and Asian were 74%, 8% and 3%, respectively; and 81% of the trial population were in the US.</p><p>Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to exenatide at 26 weeks (<a href=\\\"#t8\\\">Table 8</a> and <a href=\\\"#f05\\\">Figure 5</a>). Over the 52-week trial period, the percentage of patients who required glycemic rescue was 8.9% in the TRULICITY 0.75 mg once weekly + metformin and pioglitazone treatment group, 3.2% in the TRULICITY 1.5 mg once weekly + metformin and pioglitazone treatment group, and 8.7% in the exenatide BID + metformin and pioglitazone treatment group.</p><a name=\\\"t8\\\"></a><table width=\\\"100%\\\"><caption><span>Table 8: Results at Week 26 of TRULICITY Compared to Placebo and Exenatide, All as Add-On to Metformin and Thiazolidinedione in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.840%\\\"/><col align=\\\"left\\\" width=\\\"10.940%\\\"/><col align=\\\"left\\\" width=\\\"17.740%\\\"/><col align=\\\"left\\\" width=\\\"19.640%\\\"/><col align=\\\"left\\\" width=\\\"15.840%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: BID = twice daily; HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 23%, 10%, 7% and 12% of individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡</span> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 119, 269, 271 and 266 individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡‡</span> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to placebo, assessed only for HbA1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">††</span> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to exenatide, assessed only for HbA1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">** p&lt;0.001 TRULICITY compared to placebo, assessed only for HbA1c &lt;7.0%.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">##</span> p&lt;0.001 TRULICITY compared to exenatide, assessed only for HbA1c &lt;7.0%.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">26-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY <br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY <br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Exenatide <br/>10 mcg BID</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">‡</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">141</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">280</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">279</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">276</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rru"